FDA sets Dec. PDUFA date for Urovant rival to Astellas drug

The FDA has accepted Urovant Sciences’ filing for approval of overactive bladder prospect vibegron, teeing the biotech up to find out whether it has won approval in the final few days of 2020.

FDA sets Dec. PDUFA date for Urovant rival to Astellas drug
The FDA has accepted Urovant Sciences’ filing for approval of overactive bladder prospect vibegron, teeing the biotech up to find out whether it has won approval in the final few days of 2020.